ARC-21 (Gastrointestinal Cancer)

Purpose of this Study

We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with one of the following types of cancer:<ul>
<li>Esophageal adenocarcinoma (a common type of cancer of the esophagus); OR</li>
<li>Gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach); OR</li>
<li>Gastric adenocarcinoma (stomach cancer)</li></ul>
The cancer must not be treatable with surgery alone.

For more information about who can join this study, please contact the study team at 919-668-1861.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you choose to join this study, you will:<ul>
<li>Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks</li>
<li>Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)</li>
<li>Have blood draws</li>
<li>Get CT or MRI scans every 6-to-12 weeks</li></ul>

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

Yes

Study Details

Full Title

A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies

Principal Investigator

Hope
Uronis

Protocol Number

PRO00111012

NCT ID

NCT05329766

Phase

II

Enrollment Status

Open to Enrollment